08/01/2020 – FDA green-lights U.S. patient enrollment in masitinib phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
